| Nov 18 |
What Makes Metagenomi (MGX) a New Buy Stock
|
| Nov 15 |
Metagenomi Third Quarter 2024 Earnings: US$0.51 loss per share (vs US$3.33 loss in 3Q 2023)
|
| Nov 14 |
Metagenomi, Inc. GAAP EPS of -$0.51, revenue of $11.51M
|
| Nov 13 |
Metagenomi: Q3 Earnings Snapshot
|
| Nov 13 |
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results
|
| Nov 5 |
Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting
|
| Oct 24 |
Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT
|
| Oct 15 |
Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies
|
| Sep 19 |
Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference
|
| Sep 18 |
We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully
|
